BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007;133:755-60. [PMID: 17678921 DOI: 10.1053/j.gastro.2007.06.014] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Chang ET, Cronin-Fenton DP, Friis S, Hjalgrim H, Sørensen HT, Pedersen L. Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomarkers Prev 2010;19:59-64. [PMID: 20056623 DOI: 10.1158/1055-9965.EPI-09-0909] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
2 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
3 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
4 Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-45. [PMID: 22356286 DOI: 10.2165/11599320-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
5 Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev 2012;:CD007814. [PMID: 22895966 DOI: 10.1002/14651858.CD007814.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
6 Reimer C. Safety of long-term PPI therapy. Best Practice & Research Clinical Gastroenterology 2013;27:443-54. [DOI: 10.1016/j.bpg.2013.06.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 6.6] [Reference Citation Analysis]
7 Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860. [PMID: 18474247 DOI: 10.1053/j.gastro.2008.05.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 222] [Article Influence: 19.2] [Reference Citation Analysis]
8 Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One 2017;12:e0189114. [PMID: 29216279 DOI: 10.1371/journal.pone.0189114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
9 Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:E43. [PMID: 33375686 DOI: 10.3390/cancers13010043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chang ET, Frøslev T, Sørensen HT, Pedersen L. A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark. Br J Cancer 2011;105:1776-82. [PMID: 22027707 DOI: 10.1038/bjc.2011.443] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
11 Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, Friis S. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503-1507. [PMID: 19352380 DOI: 10.1038/sj.bjc.6605024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
12 Hálfdánarson ÓÖ, Fall K, Ogmundsdottir MH, Lund SH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471-8. [DOI: 10.1002/pds.4702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Shiratori Y, Ikeya T, Ishii N, Yamamoto K, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Arai M, Niikura R. Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps. JGH Open 2021;5:371-6. [PMID: 33732884 DOI: 10.1002/jgh3.12503] [Reference Citation Analysis]
14 Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903. [PMID: 19786155 DOI: 10.1016/j.amjmed.2009.04.014] [Cited by in Crossref: 114] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
15 Themistocleous SC, Yiallouris A, Tsioutis C, Zaravinos A, Johnson EO, Patrikios I. Clinical significance of P-class pumps in cancer. Oncol Lett 2021;22:658. [PMID: 34386080 DOI: 10.3892/ol.2021.12919] [Reference Citation Analysis]
16 Laiyemo AO, Kamangar F, Marcus PM, Taylor PR, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Atrophic gastritis and the risk of incident colorectal cancer. Cancer Causes Control 2010;21:163-70. [PMID: 19838812 DOI: 10.1007/s10552-009-9446-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
17 Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival. Curr Oncol 2016;23:e583-8. [PMID: 28050148 DOI: 10.3747/co.23.3204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
18 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
19 Ellrichmann M, Ritter PR, Schrader H, Schmidt WE, Meier JJ, Schmitz F. Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line. Regul Pept. 2010;165:146-150. [PMID: 20600355 DOI: 10.1016/j.regpep.2010.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
20 Robertson DJ, Riis AH, Friis S, Pedersen L, Baron JA, Sørensen HT. Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:1056-1061. [PMID: 20816860 DOI: 10.1016/j.cgh.2010.08.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
21 Tepeš B. Long-Term Acid Inhibition: Benefits and Harms. Dig Dis 2011;29:476-81. [DOI: 10.1159/000331519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
22 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
24 Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC. Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol. 2009;24:1810-1816. [PMID: 20002940 DOI: 10.1111/j.1440-1746.2009.06138.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
25 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
26 Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther. 2008;15:536-542. [PMID: 19127138 DOI: 10.1097/mjt.0b013e31817149bf] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
27 Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol 2017;46:80-4. [PMID: 28056391 DOI: 10.1016/j.canep.2016.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
28 Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol 2020;115:706-15. [DOI: 10.14309/ajg.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
29 Amano Y, Nakahara R, Yuki T, Murakami D, Ujihara T, Tomoyuki I, Sagami R, Suehiro S, Katsuyama Y, Hayasaka K, Harada H, Tada Y, Miyaoka Y, Fujishiro H. Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. J Gastroenterol 2019;54:984-93. [PMID: 31240437 DOI: 10.1007/s00535-019-01600-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Campos DA, de Lima AF, Ribeiro SRL, Silveira ER, Pessoa ODL, Rao VS, Santos FA. Gastroprotective effect of a flavone from Lonchocarpus araripensis Benth. (Leguminosae) and the possible mechanism. Journal of Pharmacy and Pharmacology 2008;60:391-7. [DOI: 10.1211/jpp.60.3.0016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol. 2009;7:849-854. [PMID: 19465154 DOI: 10.1016/j.cgh.2009.05.015] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
33 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
34 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
35 Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol 2009;49:444-54. [PMID: 19318694 DOI: 10.1177/0091270008330155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
36 Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol 2011;4:53-9. [DOI: 10.1007/s12328-011-0208-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
37 Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127. [PMID: 20727892 DOI: 10.1053/j.gastro.2010.08.023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
38 Bradley MC, Murray LJ, Cantwell MM, Hughes CM. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012;106:233-9. [PMID: 22108522 DOI: 10.1038/bjc.2011.511] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
39 van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966-973. [PMID: 18070237 DOI: 10.1111/j.1572-0241.2007.01665.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
40 von Rahden BH, Scheurlen M, Filser J, Stein HJ, Germer CT. [Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for GERD?]. Chirurg. 2012;83:38-44. [PMID: 21909830 DOI: 10.1007/s00104-011-2173-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
41 Sørensen HT. Case-Control Studies & the Hierarchy of Study Design. Curr Epidemiol Rep 2016;3:262-4. [DOI: 10.1007/s40471-016-0091-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66:582-591. [PMID: 22607510 DOI: 10.1111/j.1742-1241.2012.02921.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
43 Zeng R, Cheng Y, Luo D, Wang J, Yang J, Jiang L, Zhuo Z, Guo K, Wu H, Leung FW, Sha W, Chen H. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer 2021;156:190-201. [PMID: 34481369 DOI: 10.1016/j.ejca.2021.07.030] [Reference Citation Analysis]
44 Subramaniam D, Ramalingam S, May R, Dieckgraefe BK, Berg DE, Pothoulakis C, Houchen CW, Wang TC, Anant S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology. 2008;134:1070-1082. [PMID: 18395088 DOI: 10.1053/j.gastro.2008.01.040] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
45 Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M. Hypergastrinemia. Gastroenterol Rep (Oxf). 2015;3:201-208. [PMID: 25698559 DOI: 10.1093/gastro/gov004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
46 Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2018;36:1-14. [PMID: 28881340 DOI: 10.1159/000480149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
47 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Song W, Shi L, Wang Y, Zhang Z. Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis. Expert Opin Drug Saf 2021;:1-7. [PMID: 34915780 DOI: 10.1080/14740338.2022.2020245] [Reference Citation Analysis]
49 Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152:706-715. [PMID: 28257716 DOI: 10.1053/j.gastro.2017.01.031] [Cited by in Crossref: 322] [Cited by in F6Publishing: 270] [Article Influence: 64.4] [Reference Citation Analysis]
50 Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950. [PMID: 21365243 DOI: 10.1007/s10620-010-1560-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 167] [Article Influence: 17.0] [Reference Citation Analysis]
51 Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659-672. [PMID: 23647006 DOI: 10.1517/14740338.2013.797961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
52 Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sørensen HT. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res 2010;12:R15. [PMID: 20193065 DOI: 10.1186/bcr2482] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
53 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Han YM, Hahm KB, Park JM, Hong SP, Kim EH. Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model. Neoplasia 2014;16:73-83. [PMID: 24563620 DOI: 10.1593/neo.131510] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
55 Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:73-82. [PMID: 26541643 DOI: 10.1111/apt.13450] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
56 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
57 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
58 Robertson DJ, Sandler RS, Ahnen DJ, Greenberg ER, Mott LA, Cole BF, Baron JA. Gastrin, Helicobacter pylori, and colorectal adenomas. Clin Gastroenterol Hepatol. 2009;7:163-167. [PMID: 18929688 DOI: 10.1016/j.cgh.2008.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
59 Morton M, Prendergast C, Barrett TD. Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends Pharmacol Sci. 2011;32:201-205. [PMID: 21397342 DOI: 10.1016/j.tips.2011.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
60 Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 2008;44:2122-2132. [PMID: 18707867 DOI: 10.1016/j.ejca.2008.06.025] [Cited by in Crossref: 195] [Cited by in F6Publishing: 187] [Article Influence: 13.9] [Reference Citation Analysis]
61 Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010;105:1039-45. [PMID: 19904251 DOI: 10.1038/ajg.2009.629] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
62 Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 2009;18:540-4. [PMID: 19367565 DOI: 10.1002/pds.1749] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
63 Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208-14. [DOI: 10.1007/s11894-008-0045-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
64 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
65 Hsu W, Wu I, Kuo C, Su Y, Lu C, Kuo F, Jan C, Wang W, Wu D, Yu F. Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps. The Kaohsiung Journal of Medical Sciences 2010;26:76-83. [DOI: 10.1016/s1607-551x(10)70011-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
66 Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy. 2011;100:148-156. [PMID: 21784332 DOI: 10.1016/j.homp.2011.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
67 Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. Journal of Clinical Epidemiology 2010;63:422-7. [DOI: 10.1016/j.jclinepi.2009.07.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
68 Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39:984-991. [PMID: 24617286 DOI: 10.1111/apt.12693] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
69 Ahn JS, Park SM, Eom CS, Kim S, Myung SK. Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies. Korean J Fam Med 2012;33:272-9. [PMID: 23115701 DOI: 10.4082/kjfm.2012.33.5.272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
70 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
71 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 23.7] [Reference Citation Analysis]
72 de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol 2010;105:77-83. [PMID: 19724268 DOI: 10.1038/ajg.2009.503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
73 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
74 Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 2008; 14(9): 1318-1320 [PMID: 18322941 DOI: 10.3748/wjg.14.1318] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
75 Islam MM, Poly TN, Walther BA, Dubey NK, Anggraini Ningrum DN, Shabbir SA, Jack Li YC. Adverse outcomes of long-term use of proton pump inhibitors: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395-1405. [PMID: 30028775 DOI: 10.1097/meg.0000000000001198] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
76 Freston JW, Hisada M, Peura DA, Haber MM, Kovacs TO, Atkinson S, Hunt B. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2009;29:1249-60. [DOI: 10.1111/j.1365-2036.2009.03998.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
77 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
78 Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H, Sakakibara T. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154-62. [DOI: 10.1159/000484688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
79 Kuiper JG, Herk‐sukel MPP, Lemmens VEPP, Kuipers EJ, Herings RMC. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep 2020;2:165-70. [DOI: 10.1002/ygh2.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of colorectal cancer. Gut 2021:gutjnl-2021-325096. [PMID: 34210775 DOI: 10.1136/gutjnl-2021-325096] [Reference Citation Analysis]
81 Paterson AC, Macrae FA, Pizzey C, Baldwin GS, Shulkes A. Circulating gastrin concentrations in patients at increased risk of developing colorectal carcinoma: Gastrins and colorectal carcinoma risk. J Gastroenterol Hepatol 2014;29:480-6. [DOI: 10.1111/jgh.12417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
82 Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008;10:543-7. [PMID: 19006608 DOI: 10.1007/s11894-008-0100-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]